Hantz Financial Services Inc. Grows Holdings in Bio-Techne Co. (NASDAQ:TECH)

Hantz Financial Services Inc. grew its stake in shares of Bio-Techne Co. (NASDAQ:TECH) by 1.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,196 shares of the biotechnology company’s stock after buying an additional 236 shares during the quarter. Hantz Financial Services Inc.’s holdings in Bio-Techne were worth $1,023,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. UMB Bank n.a. raised its stake in shares of Bio-Techne by 46.4% during the fourth quarter. UMB Bank n.a. now owns 530 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 168 shares in the last quarter. Brooklyn Investment Group purchased a new position in Bio-Techne in the 3rd quarter worth $39,000. Quest Partners LLC bought a new stake in Bio-Techne in the third quarter worth $43,000. MassMutual Private Wealth & Trust FSB boosted its position in Bio-Techne by 60.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 672 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 253 shares during the period. Finally, Mather Group LLC. grew its stake in shares of Bio-Techne by 51.5% during the third quarter. Mather Group LLC. now owns 612 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 208 shares during the last quarter. 98.95% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Bio-Techne news, CEO Kim Kelderman sold 13,392 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $77.29, for a total transaction of $1,035,067.68. Following the sale, the chief executive officer now directly owns 39,004 shares in the company, valued at $3,014,619.16. This represents a 25.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. 3.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on TECH shares. Robert W. Baird raised their price target on Bio-Techne from $82.00 to $84.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Scotiabank lifted their target price on shares of Bio-Techne from $83.00 to $88.00 and gave the stock a “sector outperform” rating in a research note on Thursday, October 31st. Finally, StockNews.com raised shares of Bio-Techne from a “hold” rating to a “buy” rating in a research report on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $82.00.

Bio-Techne Trading Up 1.1 %

Shares of TECH stock opened at $73.55 on Friday. The company has a market cap of $11.69 billion, a price-to-earnings ratio of 78.25, a PEG ratio of 5.30 and a beta of 1.27. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.56 and a quick ratio of 3.26. The firm has a fifty day moving average price of $74.72 and a 200-day moving average price of $74.48. Bio-Techne Co. has a 1 year low of $61.16 and a 1 year high of $85.57.

Bio-Techne (NASDAQ:TECH) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.38 by $0.04. The business had revenue of $289.46 million for the quarter, compared to analysts’ expectations of $280.22 million. Bio-Techne had a net margin of 12.86% and a return on equity of 12.76%. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.35 EPS. As a group, equities analysts predict that Bio-Techne Co. will post 1.68 earnings per share for the current year.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.